PMC:7386875 / 49609-50606 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T499","span":{"begin":87,"end":94},"obj":"Body_part"},{"id":"T500","span":{"begin":170,"end":177},"obj":"Body_part"},{"id":"T501","span":{"begin":230,"end":235},"obj":"Body_part"},{"id":"T502","span":{"begin":381,"end":389},"obj":"Body_part"},{"id":"T503","span":{"begin":532,"end":539},"obj":"Body_part"},{"id":"T504","span":{"begin":732,"end":739},"obj":"Body_part"},{"id":"T505","span":{"begin":762,"end":769},"obj":"Body_part"},{"id":"T506","span":{"begin":918,"end":925},"obj":"Body_part"}],"attributes":[{"id":"A499","pred":"fma_id","subj":"T499","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A500","pred":"fma_id","subj":"T500","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A501","pred":"fma_id","subj":"T501","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A502","pred":"fma_id","subj":"T502","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A503","pred":"fma_id","subj":"T503","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A504","pred":"fma_id","subj":"T504","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A505","pred":"fma_id","subj":"T505","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A506","pred":"fma_id","subj":"T506","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T366","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"T367","span":{"begin":181,"end":189},"obj":"Disease"},{"id":"T368","span":{"begin":302,"end":310},"obj":"Disease"},{"id":"T369","span":{"begin":411,"end":419},"obj":"Disease"},{"id":"T370","span":{"begin":579,"end":587},"obj":"Disease"},{"id":"T371","span":{"begin":762,"end":794},"obj":"Disease"},{"id":"T372","span":{"begin":778,"end":794},"obj":"Disease"},{"id":"T373","span":{"begin":827,"end":843},"obj":"Disease"},{"id":"T374","span":{"begin":848,"end":858},"obj":"Disease"},{"id":"T375","span":{"begin":889,"end":897},"obj":"Disease"},{"id":"T376","span":{"begin":918,"end":950},"obj":"Disease"},{"id":"T377","span":{"begin":934,"end":950},"obj":"Disease"}],"attributes":[{"id":"A366","pred":"mondo_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A367","pred":"mondo_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A368","pred":"mondo_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A369","pred":"mondo_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A370","pred":"mondo_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0018048"},{"id":"A372","pred":"mondo_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A373","pred":"mondo_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A374","pred":"mondo_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A375","pred":"mondo_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A376","pred":"mondo_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/MONDO_0018048"},{"id":"A377","pred":"mondo_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T528","span":{"begin":49,"end":54},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T529","span":{"begin":230,"end":235},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T530","span":{"begin":994,"end":997},"obj":"http://purl.obolibrary.org/obo/CLO_0001079"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T41445","span":{"begin":87,"end":94},"obj":"Chemical"},{"id":"T78519","span":{"begin":98,"end":111},"obj":"Chemical"},{"id":"T91720","span":{"begin":170,"end":177},"obj":"Chemical"},{"id":"T86020","span":{"begin":381,"end":389},"obj":"Chemical"},{"id":"T52927","span":{"begin":532,"end":539},"obj":"Chemical"},{"id":"T82903","span":{"begin":732,"end":739},"obj":"Chemical"},{"id":"T22341","span":{"begin":762,"end":769},"obj":"Chemical"},{"id":"T42905","span":{"begin":918,"end":925},"obj":"Chemical"}],"attributes":[{"id":"A62091","pred":"chebi_id","subj":"T41445","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A20724","pred":"chebi_id","subj":"T78519","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"},{"id":"A24811","pred":"chebi_id","subj":"T91720","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A57821","pred":"chebi_id","subj":"T86020","obj":"http://purl.obolibrary.org/obo/CHEBI_24505"},{"id":"A35503","pred":"chebi_id","subj":"T52927","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A43081","pred":"chebi_id","subj":"T82903","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A27886","pred":"chebi_id","subj":"T22341","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A90354","pred":"chebi_id","subj":"T42905","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T70","span":{"begin":762,"end":794},"obj":"Phenotype"},{"id":"T71","span":{"begin":827,"end":843},"obj":"Phenotype"},{"id":"T72","span":{"begin":918,"end":950},"obj":"Phenotype"}],"attributes":[{"id":"A70","pred":"hp_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/HP_0011874"},{"id":"A71","pred":"hp_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A72","pred":"hp_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/HP_0011874"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-sentences","denotations":[{"id":"T169","span":{"begin":0,"end":313},"obj":"Sentence"},{"id":"T170","span":{"begin":314,"end":625},"obj":"Sentence"},{"id":"T171","span":{"begin":626,"end":997},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"2_test","denotations":[{"id":"32586214-19321428-21597819","span":{"begin":236,"end":239},"obj":"19321428"},{"id":"32586214-11746174-21597820","span":{"begin":675,"end":678},"obj":"11746174"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1663","span":{"begin":145,"end":148},"obj":"Gene"},{"id":"1664","span":{"begin":164,"end":169},"obj":"Gene"},{"id":"1665","span":{"begin":38,"end":48},"obj":"Species"},{"id":"1666","span":{"begin":181,"end":189},"obj":"Species"},{"id":"1667","span":{"begin":302,"end":312},"obj":"Species"},{"id":"1668","span":{"begin":565,"end":573},"obj":"Species"},{"id":"1669","span":{"begin":87,"end":94},"obj":"Chemical"},{"id":"1670","span":{"begin":381,"end":389},"obj":"Chemical"},{"id":"1671","span":{"begin":532,"end":539},"obj":"Chemical"},{"id":"1672","span":{"begin":732,"end":739},"obj":"Chemical"},{"id":"1673","span":{"begin":762,"end":769},"obj":"Chemical"},{"id":"1674","span":{"begin":918,"end":925},"obj":"Chemical"},{"id":"1675","span":{"begin":411,"end":419},"obj":"Disease"},{"id":"1676","span":{"begin":579,"end":587},"obj":"Disease"},{"id":"1677","span":{"begin":778,"end":794},"obj":"Disease"},{"id":"1678","span":{"begin":827,"end":843},"obj":"Disease"},{"id":"1679","span":{"begin":848,"end":858},"obj":"Disease"},{"id":"1680","span":{"begin":889,"end":897},"obj":"Disease"},{"id":"1681","span":{"begin":934,"end":950},"obj":"Disease"}],"attributes":[{"id":"A1663","pred":"tao:has_database_id","subj":"1663","obj":"Gene:2159"},{"id":"A1664","pred":"tao:has_database_id","subj":"1664","obj":"Gene:43740568"},{"id":"A1665","pred":"tao:has_database_id","subj":"1665","obj":"Tax:2697049"},{"id":"A1666","pred":"tao:has_database_id","subj":"1666","obj":"Tax:694009"},{"id":"A1667","pred":"tao:has_database_id","subj":"1667","obj":"Tax:2697049"},{"id":"A1668","pred":"tao:has_database_id","subj":"1668","obj":"Tax:9606"},{"id":"A1669","pred":"tao:has_database_id","subj":"1669","obj":"MESH:D006493"},{"id":"A1670","pred":"tao:has_database_id","subj":"1670","obj":"MESH:D006493"},{"id":"A1671","pred":"tao:has_database_id","subj":"1671","obj":"MESH:D006493"},{"id":"A1672","pred":"tao:has_database_id","subj":"1672","obj":"MESH:D006493"},{"id":"A1673","pred":"tao:has_database_id","subj":"1673","obj":"MESH:D006493"},{"id":"A1674","pred":"tao:has_database_id","subj":"1674","obj":"MESH:D006493"},{"id":"A1675","pred":"tao:has_database_id","subj":"1675","obj":"MESH:C000657245"},{"id":"A1676","pred":"tao:has_database_id","subj":"1676","obj":"MESH:C000657245"},{"id":"A1677","pred":"tao:has_database_id","subj":"1677","obj":"MESH:D013921"},{"id":"A1678","pred":"tao:has_database_id","subj":"1678","obj":"MESH:D013921"},{"id":"A1679","pred":"tao:has_database_id","subj":"1679","obj":"MESH:D013927"},{"id":"A1680","pred":"tao:has_database_id","subj":"1680","obj":"MESH:C000657245"},{"id":"A1681","pred":"tao:has_database_id","subj":"1681","obj":"MESH:D013921"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Another interesting aspect of how the SARS-CoV-2 virus may be influenced by the use of heparin as anticoagulant is the previous observation that FXa can cleave the spike protein of SARS-CoV to render it more efficient in invading cells.147 However, to date, this aspect remains to be investigated with SARS-CoV-2. These data have led some groups to propose specifically engineered heparins for the treatment of COVID-19, while clinical trials are underway to investigate the effects of low dose, and full-dose, anticoagulation with heparin on clinical outcomes for patients with COVID-19 (URL: https://www.clinicaltrials.gov. Unique identifiers: NCT04344756 and NCT04345848).142 It is important to note that given the potential for heparin therapeutics to cause heparin-induced thrombocytopenia, but reassuringly, despite both thrombocytopenia and thrombosis being common complications of COVID-19, the development of heparin-induced thrombocytopenia appears limited to individual case reports.148"}